For the first quarter of 2026, Boston Scientific reported net sales of $5.203 billion, representing an 11.6% increase on a reported basis and a 9.4% increase on an organic basis compared to the prior year. Adjusted EPS came in at $0.80, representing solid growth from $0.75 in the same quarter last year, driven by robust performance across both the MedSurg and Cardiovascular segments.
Note: Boston Scientific's FY'25 ended on December 31, 2025. Q1 FY'26 ended on March 31, 2026.
During the quarter, Boston Scientific completed the strategic acquisition of Valencia Technologies to bolster its urology portfolio with the eCoin System, and announced positive long-term outcomes for its FARAPULSE Pulsed Field Ablation system, which continues to drive significant market share gains.
Below are key drivers of Boston Scientific's value that present opportunities for upside or downside to the current Trefis price estimate:
For additional details, select a division from the interactive Trefis split for Boston Scientific at the top of the page.
Boston Scientific is a global developer, manufacturer, and marketer of medical devices that are used in a broad range of interventional medical specialties, generating revenue primarily through the sale of these devices to hospitals and clinics across its MedSurg and Cardiovascular segments.
The Cardiovascular segment stands as the most valuable piece of Boston Scientific's business due to its high-growth categories and premium margin profile.
The company has established a commanding presence in high-growth markets like left atrial appendage closure with its WATCHMAN devices and pulsed field ablation with FARAPULSE, benefiting from a massive installed base and strong clinical data that lock in hospital contracts.
Boston Scientific boasts a highly diversified product ecosystem across cardiology, endoscopy, and urology, creating a wide economic moat as hospitals prefer to consolidate vendors and bundle device purchases for better pricing and workflow integration.
The medical device industry is rapidly shifting toward pulsed field ablation for treating atrial fibrillation due to its superior safety profile over traditional thermal ablation, and Boston Scientific is currently positioned as a first-mover and market leader in this high-growth category.
The company continues to lean into a tuck-in acquisition strategy, recently buying companies like Nalu Medical, Valencia Technologies, and Penumbra to continuously replenish its pipeline, expand into adjacent high-growth markets, and offset pricing pressures in legacy product lines.
